Andrew Fein
Analyst at H.C. Wainwright
Ticker Coverage
Sector Coverage
Mentions in the News
Biogen Analysts Divided Over Alzheimer's Drug Following CTAD Presentation
Following Biogen Inc's (NASDAQ: BIIB) presentation of detailed top-line results for aducanumab at the Alzheimer's conference, the stock ended Thursday's session up about 3.5%. Cantor Fitzgerald analyst Alethia Young maintained a Neutral rating and $300 price …
Published: Dec 6 2019
How Much Higher Can Amarin (AMRN) Stock Go Following FDA Approval?
Amarin (AMRN) investors received a nice gift going into the weekend, after shares of the biopharma increased by almost 12% on Friday. The boost came on the heels of Thursday’s FDA AdCom vote in favor of extending the label on the company’s flagship drug, Vasc…
Published: Nov 18 2019
Would you like to be included in the directory? Let us know!
© Street Contxt. All Rights Reserved.